Table 1
From: A novel method of modifying immune responses by vaccination with lipiodol-siRNA mixtures
| Â | Surface molecules (MFI) | ||
|---|---|---|---|
| Â | CD80 | CD86 | CD40 |
Unactivated DC | Â | Â | Â |
Media Control | 571.7 (± 23) | 1194 (± 125) | 29.5 (± 1.5) |
Lipiodol Control | 567.3 (± 21) | 1251 (± 173) | 28.6 (± 1.3) |
Mixed siRNA | 572.5 (± 10) | 1365 (± 157) | 29.7 (± 1.3) |
siRNA alone | 559.6 (± 33) | 1201 (± 193) | 30.1 (± 0.9) |
siRNA + Lipiodol | 577.3 (± 15) | 1195 (± 103) | 30.4 (± 1.3) |
Post-MLR | Â | Â | Â |
Lipiodol Control | 1962.9 (± 136) | 2707.1 (± 576) | 140.5 (± 35.4) |
Mixed siRNA | 1933.2 (± 324) | 3031.6 (± 489) | 170.3 (± 26.9) |
siRNA alone | 1905.7 (± 351) | 2759.9 (± 392) | 167.2 (± 46.9) |
siRNA + Lipiodol | 2050.8 (± 119) | 3051.1 (± 335) | 153.3 (± 36.7) |
Post-MLR + Anti-IL10 | Â | Â | Â |
Lipiodol Control | 3529 (± 302) | 4862 (± 583) | 236.0 (± 47.3) |
Mixed siRNA | 3442 (± 247) | 4777 (± 773) | 242.8 (± 58.9) |
siRNA alone | 3723 (± 453) | 4863 (± 669) | 237.4 (± 43.5) |
siRNA + Lipiodol | 3985 (± 339) | 4957 (± 501) | 254.3 (± 49.3) |